窪蹋勛圖厙 Executives Talk About Going Global, Shifting Focus
Within the last 100 years, 窪蹋勛圖厙 core success was founded on its technology and innovation, according to COO Nacho Abia. To those outside of the organization, 窪蹋勛圖厙 pervasive branding as the camera company still sticks, despite the in 2020. The company continues to pivot, and with recent of impressive earnings in FY22, a listen back to a January 2022 MassDevice in which Nacho was interviewed, along with Gabriela Kaynor, Division Head of Therapeutics Solutions, proves insightful to some of these shifts.
Whats being transformed?
During the interview, Nacho recalled 窪蹋勛圖厙 CEO Yasuo Takeuchi rolling out a very disruptive and aggressive agenda of change after his appointment in 2019. He wanted 窪蹋勛圖厙 to be the number one medical device company so that significant investment and resources would be allocated to devices and technology in the business. Secondly, he wanted to globalize the company, and transform it from a very powerful, solid Japanese company into a truly global enterprise that can operate and utilize talent from all over the world, Nacho explained. The transformation plan was in January 2019.
Previously, 窪蹋勛圖厙 was segmented into three divisions: scientific solutions, the medical business, and the consumer (camera) business, with the decision-making process for all units taking place in Japan, Nacho said.
Decades of market and economic shifts fostered the decision to transform 窪蹋勛圖厙. Nacho explained that while the consumer camera market peaked in the late 1990s, the proliferation of smartphonesand ultimately the iPhone簧 in the early 2000scut into this market share. But at the same time, the medical business was booming.
Fast forward to the present
Its true that our branding has been built based on the camera business, Nacho said during the podcast, but explained that 窪蹋勛圖厙 refocused and zoomed in on healthcare.
Nacho Abia, COO, and Gabriela Kaynor, Division Head of Therapeutics Solutions
Most of our products come from early diagnosis and minimally invasive treatment based on the fact that we provide minimally invasive access through either flexible endoscopes or rigid endoscopes, he said. Today, the areas where were really making a difference is GI, respiratory, and urology. Now we are leading in those spaces. Also, We have a very strong franchise in surgical imaging, laparoscopy, we also have electrosurgery devices [and] we are also very strong in ENT. In addition to endoscopes to provide access and visualization, Over the years, our relationship with [healthcare providers] has helped to evolve the therapeutic offerings, allowing 窪蹋勛圖厙 to add to its portfolio.
Therapeutic solutions in the Boston area
In the medical world, Nacho explained that we now have two large divisions: therapeutics solutions and endoscopic solutions. Therapeutics solutions is a newly created division located in Westborough, Mass.
Until being tapped on the shoulder I didnt understand all of the areas and segments of the markets that 窪蹋勛圖厙 played in, admitted Gabriela. She joined 窪蹋勛圖厙 in 2016 and is based in the new Westborough office. She previously worked at Johnson & Johnson and Covidien. Were playing across multiple specialties but from a mission perspective were looking to deliver profitable and sustainable growth.
Gabriela has seen this mission play out through the transformation efforts over the last three years. That transformation effort for us has really been part of looking outside [of the company and] trying to expand beyond endoscopy, she said. As technologies in other areas advance, 窪蹋勛圖厙 is adopting them and developing alternative solutions. One key area of interest is in single-use products.
Beyond capital equipment
Traditionally 窪蹋勛圖厙 focus has been on the endoscopy capital side. But the company is becoming more agile in the way we develop and commercialize the single-use devices and solutions for our customers, she said.
R&D is still a component of the business, but supply chain [management], procurement, partnerships, distribution, and commercialization become the larger perspective, Gabriela explained. To the last point, she added that the company recognizes a need to provide a more value-based commercial approach.
She said the global focus of the company is about shifting that mentality from working as functional silos. Five years ago, we were operating much more as regions and now there is a cross-functional push, she explained. That doesnt come without its growing pains, but with great global teams 窪蹋勛圖厙 continues to evolve, fostered by new talent and new processes, she added.
The Westborough location bolsters top-notch recruitment. Obviously, Massachusetts is a great area to attract talent given the number of universities and medical device companies in the Boston area, Gabriela observed. In the bigger picture, Were committed to improving our value chain here in the United States and that includes not just the commercial front but every global function.
Hear the entire podcast from January 7, 2022:
